Sanofi: cross-border access for the specialty portfolio

Quick orientation

Sanofi is a French multinational pharmaceutical company headquartered in Paris, with US operations centered in Bridgewater, New Jersey, and the rare-disease subsidiary Sanofi Genzyme based in Cambridge, Massachusetts. Sanofi's specialty footprint is anchored in immunology (Dupixent co-marketed with Regeneron is the largest Sanofi product), rare disease (the Genzyme lysosomal storage disease franchise Cerezyme, Fabrazyme, Aldurazyme, Myozyme, Nexviazyme; Pombiliti in Pompe disease; Xenpozyme in acid sphingomyelinase deficiency), oncology (Sarclisa in multiple myeloma; Cabometyx co-marketed with Exelixis; Jevtana in metastatic CRPC), vaccines (Beyfortus, Fluzone, MenQuadfi), hemophilia (Altuviiio for hemophilia A), and multiple sclerosis (Aubagio, Lemtrada).

Portfolio in cross-border NPP scope

Dupixent (dupilumab, co-marketed with Regeneron)

IL-4-receptor-alpha monoclonal antibody approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD with type 2 inflammation, and chronic spontaneous urticaria. US WAC at the standard 300mg every-two-weeks adult dose runs above $40,000 per year. Cross-border requests cluster around pediatric atopic dermatitis weight-banded dosing, EoE, and the newer COPD and CSU indications not yet locally registered.

Cerezyme (imiglucerase)

Recombinant beta-glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. International requests come from Gaucher patients in MENA and India where the locally registered supply is intermittent or where Cerezyme specifically is preferred over velaglucerase alfa or taliglucerase alfa.

Fabrazyme (agalsidase beta)

Enzyme replacement therapy for Fabry disease. Cross-border requests come from Fabry patients in MENA and India where the locally available supply has been intermittent during global manufacturing constraints, or where the pediatric indication is not yet locally registered.

Nexviazyme (avalglucosidase alfa)

Newer-generation enzyme replacement therapy for late-onset Pompe disease. International requests come from Pompe disease patients in MENA and India who want Nexviazyme specifically over alglucosidase alfa.

Xenpozyme (olipudase alfa) and Cerdelga (eliglustat)

Xenpozyme is enzyme replacement therapy for non-CNS manifestations of acid sphingomyelinase deficiency. Cerdelga is an oral glucosylceramide synthase inhibitor for type 1 Gaucher disease in CYP2D6 extensive or intermediate metabolizers. International requests come from rare-disease specialty centers in MENA and India where these specific molecules are not locally registered.

Sarclisa (isatuximab)

CD38-directed monoclonal antibody approved for multiple myeloma in combination with pomalidomide and dexamethasone, and with carfilzomib and dexamethasone. Cross-border requests come from myeloma patients in MENA and India who have failed daratumumab and need an alternative CD38 monoclonal antibody.

Beyfortus (nirsevimab, co-marketed with AstraZeneca)

Long-acting monoclonal antibody approved for prevention of RSV lower respiratory tract disease in neonates and infants. International requests come from neonatology centers in MENA and the Gulf where Beyfortus is not yet locally registered as standard infant RSV prophylaxis.

Altuviiio (efanesoctocog alfa)

Once-weekly factor VIII replacement therapy with extended half-life for hemophilia A. Cross-border requests come from hemophilia A centers in MENA and India where the weekly dosing schedule simplifies pediatric and adult prophylaxis.

Aubagio (teriflunomide) and Lemtrada (alemtuzumab)

The Sanofi-Genzyme MS franchise. International requests come from MS patients in MENA and India where the locally available MS biologics do not include these specific molecules.

Why patients route Sanofi products through cross-border NPP

Three patterns dominate. First, the Sanofi Genzyme rare-disease franchise (Gaucher, Fabry, Pompe, MPS-I, ASMD) operates at very small patient populations where local registration timing and supply reliability vary by country. Second, Dupixent indication expansion velocity (COPD with type 2 inflammation, CSU) outpaces MENA and India payer formulary updates. Third, the Sanofi Patient Connection program is restricted to US residents.

Manufacturer engagement posture

Reserve Meds coordinates Sanofi and Sanofi Genzyme-manufactured US product through DSCSA-compliant specialty wholesaler channels. We are not an authorized Sanofi distributor. All Reserve Meds orders are cash-pay at firm-quote pricing.

For Sanofi and Sanofi Genzyme market access teams: Reserve Meds maintains structured demand visibility across rare-disease, immunology, hemophilia, and oncology franchises. If your group is sizing supply-gap demand in lysosomal storage diseases or pre-registration demand for newer Dupixent indications, we are open to a structured conversation under NDA.

Common cross-border destinations for the Sanofi portfolio

The Sanofi Genzyme rare-disease franchise concentrates in tertiary specialty centers in the UAE, Saudi Arabia, India, Egypt, and Kuwait where Gaucher, Fabry, and Pompe patient registries exist. Dupixent demand is broadest, spanning the Gulf and India. The hemophilia and oncology franchises track tertiary specialty center concentration.

What Reserve Meds provides

For every Sanofi product order, Reserve Meds coordinates DSCSA chain-of-custody documentation; cold-chain validated logistics where required; country regulatory pathway expertise covering named-patient import approval, customs clearance, and any required physician declaration; and a single patient-facing coordinator. We do not replace the patient's treating physician. A US-licensed pharmacist reviews every prescription before dispensing.

Next step for patients

Patients or caregivers who have a treating physician's prescription for a Sanofi product and want a firm quote can start a request below.

Start a request for a Sanofi product

Next step for Sanofi teams

If you are on the Sanofi access, medical affairs, or international market access team and want to discuss coordinated named-patient program demand from MENA and India, reach us at [email protected]. We will share aggregated demand views under NDA.

Reserved for you.